PTABWatch Blog
http://www.ptabwatch.com/author/jsakevich/PTABWatch, provided by Marshall, Gerstein & Borun LLP, analyzes and reports recent developments concerning Post-Grant Proceedings at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), including Inter Partes Review (IPR), Post Grant Review (PGR), and Covered Business Method (CBM) proceedings.
Recent Blog Posts
- Petitioner’s Analogous Art Argument was not so Obvious when Reversing the PTAB In Sanofi-Aventis Deutschland GMBH v. Mylan Pharms, Inc., No. 21-1981 (Fed. Cir. May 9, 2023), the Federal Circuit reversed the PTAB’s finding that Sanofi’s patent claims were obvious, determining the PTAB used the wrong test for deciding whether an existing patent was “analogous” to the one being challenged. Mylan Pharmaceuticals had asserted all claims of Sanofi’s U.S. Patent No. RE47,614 directed to a drug delivery device were obvious in view of a combination of three references. All challenged claims required a... More